Sinopharm Group Co. Ltd.
SHTDY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.40 | 1.03 | 0.66 | 0.71 |
| FCF Yield | 15.49% | 25.67% | 34.22% | 16.51% |
| EV / EBITDA | 4.16 | 2.52 | 2.61 | 2.74 |
| Quality | ||||
| ROIC | 5.82% | 7.83% | 8.63% | 8.76% |
| Gross Margin | 7.57% | 8.13% | 8.59% | 8.45% |
| Cash Conversion Ratio | 0.82 | 0.88 | 1.13 | 0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.92% | 4.61% | 6.55% | 7.01% |
| Free Cash Flow Growth | -35.45% | -20.00% | 162.98% | -22.22% |
| Safety | ||||
| Net Debt / EBITDA | 1.09 | 0.37 | 0.55 | 1.01 |
| Interest Coverage | 5.92 | 6.84 | 5.85 | 5.25 |
| Efficiency | ||||
| Inventory Turnover | 8.66 | 9.13 | 8.28 | 9.26 |
| Cash Conversion Cycle | 65.23 | 50.59 | 52.65 | 58.63 |